Should medical researchers share their results with the volunteers in their studies?

Jun 06, 2008

Every year, hundreds of thousands of Americans volunteer to take part in medical research studies, from simple health surveys to detailed analyses of their DNA or tests of experimental medicines.

But what happens after their participation is over? In many cases, volunteers won't ever hear from the researchers about what the study revealed. But other studies make a special effort to keep volunteers informed, via newsletters or Web sites.

A new review of the issue, published recently in the journal Public Library of Science Medicine, suggests that participants' desire to know the results of studies outweighs concerns by some bioethicists about the potential negative psychological consequences of sharing some results. Even when it's bad news, most study volunteers want to know.

So, should all medical researchers make an effort to communicate about their results with the volunteers who are so vital to their research? If they try to do so, what hurdles — ethical, privacy-related, financial or logistical — might complicate their efforts? Could sharing clinical research results with some volunteers actually upset them?

Such questions are addressed in the new paper, which was written by University of Michigan medical student David Shalowitz and Franklin Miller, Ph.D., of the Department of Bioethics at the National Institutes of Health. The research was funded by a grant from the U-M President's Initiative for Ethics in Public Life.

The paper reviews the landscape of knowledge on this issue, including commentaries on the potential positive and negative impacts of sharing results, and data from studies that evaluated the desires and reactions of research volunteers in specific clinical trials.

All in all, the article says, better data are needed on the ins and outs of sharing study results with research volunteers.

"It's a mixed bag," says lead author Shalowitz. "We found overwhelmingly that participants do want access to aggregate study results, and that to a lesser extent they want to know their individual results if they have relevance to their lives."

For instance, volunteers in a study looking for genes related to a particular disease might appreciate the opportunity to find out what their individual genetic test revealed. And they may be interested in learning what the entire study found.

But other people in the same study might not want to know their individual results, for fear of finding out that they have a higher risk of developing a particular disease.

One of the biggest hurdles that the authors found in both commentaries and studies of this issue, Shalowitz says, was the cost of contacting research volunteers and presenting trial results to them.

Presenting aggregate results in layman's language is not as difficult, he notes, as preparing individual reports for each volunteer, which can be very labor-intensive in a large study with hundreds or thousands of participants.

Then there's the ethical issue of whether and how to offer participants a way to communicate with the researchers about what they've been told – for instance, by phone or e-mail if they're concerned about their individual test results.

And, for those who simply don't want to know their individual results or even the aggregate results, a system for opting out is needed.

These considerations might be addressed if researchers consider participant communications during the earliest planning of their study, including the funding request, Shalowitz says.

If the NIH and local Institutional Review Boards were to demand a plan for such communications as part of each study proposal, and perhaps provide staff who could facilitate such efforts, it would help researchers greatly, he adds.

In the end, the authors say, more research on the best approaches for contacting research volunteers, and the actual responses of volunteers to this issue, is needed.

"There's a need to develop a standard way of measuring these domains, so that systematic evaluations can be done," says Shalowitz. "We also need better evaluations of the best ways to communicate data to research participants. We need to change the current situation in which claims are being made about the benefits and risks of sharing results without data to back them up."

Source: University of Michigan

Explore further: Using feminist theory to understand male rape

add to favorites email to friend print save as pdf

Related Stories

'Red effect' sparks interest in female monkeys

1 hour ago

Recent studies showed that the color red tends increase our attraction toward others, feelings of jealousy, and even reaction times. Now, new research shows that female monkeys also respond to the color red, ...

Tailored 'activity coaching' by smartphone

3 hours ago

Today's smartphone user can obtain a lot of data about his or her health, thanks to built-in or separate sensors. Researcher Harm op den Akker of the University of Twente (CTIT Institute) now takes this health ...

Recommended for you

Using feminist theory to understand male rape

39 minutes ago

Decades of feminist research have framed rape and sexual assault as a 'women's issue', leaving little room for the experiences of male victims. But a new study published in the Journal of Gender Studies suggests that feminist ...

Simulation-based training improves endoscopy execution

Oct 18, 2014

(HealthDay)—Simulation-based training (SBT) improves clinicians' performance of gastrointestinal endoscopy in both test settings and clinical practice, according to research published in the October issue ...

Data sharing in pharmaceutical industry shows progress

Oct 16, 2014

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Swiss drug maker Roche posts flat 3Q sales

Oct 16, 2014

(AP)—Swiss drugmaker Roche Holding AG has reported "stable" or flat sales for the first nine months of 2013 but says the results show strong demand for its cancer drugs and emerging new products.

User comments : 0